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Abstract
Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG
Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab
to chemotherapy in the adjuvant setting for HER2þ breast cancer patients. NSABP investigators utilized gene expression pro-
files of N9831 patients (N¼892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then
NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen recep-
tor/progesterone receptor status, tumor size, and grade. Hazard ratios and 2-sided P values for recurrence-free survival of the
predicted large- (n¼387), moderate- (n¼401), and no-benefit (n¼104) groups, based on the 8-gene signature were 0.47 (95%
CI¼0.31 to 0.73, P < .001), 0.60 (95% CI¼0.39 to 0.92, P ¼ .02), and 1.54 (95% CI¼0.59 to 4.02, P ¼ .38), respectively (Pinteraction ¼
.02), providing validation of the 8-gene signature in an independent study.
Several breast cancer clinical trials including HERA (Herceptin
Adjuvant Trial), B-31, N9831, FinHer (Finland Herceptin Study),
and BCIRG-006 (Breast Cancer International Research Group),
demonstrated that chemotherapy-plus-trastuzumab improved
outcomes for HER2þ breast cancer patients in the adjuvant set-
ting (1–4). We previously described an 8-gene signature devel-
oped in a discovery cohort of NRG Oncology/NSABP B-31
(NCT00004067) patients to predict the degree of trastuzumab
benefit, which was validated in an independent B-31 patient co-
hort (5). In the validation cohort, the 8-gene signature subtyped
B-31 tumors into three trastuzumab-benefit groups: large- (haz-
ard ratios [HR] ¼ 0.28, 95% confidence interval [CI]¼ 0.20 to 0.41,
P < .001), moderate- (HR¼ 0.60, 95% CI¼ 0.41 to 0.89, P ¼ .01),
and no-benefit (HR¼ 1.58, 95% CI¼ 0.67 to 3.69, P ¼ .29)
(Pinteraction < .001).
Our purpose was to validate the predictive ability of the 8-
gene signature in Alliance/NCCTG N9831 (NCT00898898), which
had three arms: Arm A (chemotherapy only), Arm B (trastuzumab
after chemotherapy), or Arm C (trastuzumab given concurrently
with chemotherapy). Patients from Arm B were not used for this
study. There were no statistically significant differences between
B-31 and N9831 Arms A and C in clinical covariates except nodal
status. N9831 included node-positive and node-negative patients.
B-31 only included node-positive patients (Table 1).
N9831 cases were profiled with two custom nCounter code
sets but only data for the 8 signature genes (CA12, ERBB2, ESR1,
GATA3, GRB7, IGF1R, NAT1, MIEN1) and 16 housekeeping genes
were sent to NSABP investigators for signature validation.
Patient consent, data analysis work flow (Supplementary Figure
1, available online), and statistical methods are discussed in the
Supplementary Methods (available online). All NSABP investiga-
tors were blinded to all clinical data. Patients were assigned a
predicted trastuzumab-benefit group (large-, moderate-, or no-
benefit) based on the 8-gene signature analysis. Details are
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included in the Supplementary Material (available online) and
the original validation manuscript (5). Predictions were sent to
N9831 investigators and prediction accuracy was tested in the
chemotherapy arm (A) (n¼ 480) and the trastuzumab-plus-
chemotherapy arm (C) (n¼ 412) using Cox models adjusted for
age, nodes, estrogen receptor/progesterone receptor (ER/
PR) status, tumor size, and grade. Only N9831 Arms A and C
were analyzed because of their similarity to B-31 arms.
Numbers of patients assigned to the predicted large-, moder-
ate-, and no-benefit groups were 387 (43.4%), 401 (45.0%), and
104 (11.7%), respectively. Respective recurrence-free survival
(RFS) hazard ratios for trastuzumab benefit were 0.47 (95%
CI¼ 0.31 to 0.73, P < .001), 0.6 (95% CI¼ 0.39 to 0.92, P ¼ .02), and
1.54 (95% CI¼ 0.59 to 4.02, P ¼ .38) in adjusted Cox models
(Pinteraction ¼ .02) (Figure 1). Ten-year RFS for trastuzumab-
treated patients was 82.5% (95% CI¼ 77.2% to 88.2%), 83.1% (95%
CI¼ 77.6% to 89.1%), and 71.5% (95% CI¼ 58.9% to 86.8%), in the
large-, moderate-, and no-benefit groups, respectively.
Patients in the predicted large-, moderate- and no-benefit
groups had disease-free survival (DFS) hazard ratios for trastu-
zumab benefit of 0.57 (95% CI¼ 0.40 to 0.82, P ¼ .002), 0.66 (95%
CI¼ 0.46 to 0.95, P ¼ .02), and 1.13 (95% CI¼ 0.49 to 2.61, P ¼ .77),
respectively. The Pinteraction approached significance (P ¼ .10) in
adjusted Cox models (Supplementary Material Figure 2, avail-
able online). Ten-year DFS for trastuzumab-treated patients
was 75.4% (95% CI¼ 69% to 82%), 76.2% (95% CI¼ 70% to 83%),
and 71.5% (95% CI¼ 59% to 87%) in the large-, moderate-, and
no-benefit groups, respectively.
N9831 results further validate the observation made in B-31
that the 8-gene signature may identify a relatively small, but
potentially important subset of HER2þ patients who do not ap-
pear to benefit from trastuzumab. The differences between the
large- and moderate-benefit groups in N9831 were less apparent
than in the validation cohort of B-31, but that distinction would
be of negligible clinical utility relative to identification of a sub-
set of HER2þ patients deriving minimal, if any, benefit from
trastuzumab.
Joint analysis of N9831 and B-31 established trastuzumab-
plus-chemotherapy as a standard of care (SOC) for HER2þ breast
cancer (2,6). Subsequently, the APHINITY (NCT01358877) trial
established dual-HER2-targeted therapy with chemotherapy as
the current SOC of newly diagnosed, high-risk HER2þ early-
stage breast cancer, most often administered in the neoadju-
vant setting, with administration of adjuvant T-DM1 for
patients with residual invasive cancer following neoadjuvant
chemotherapy and HER2-targeted therapy (7–9).
The 8-gene signature identifies a patient group that did not
receive benefit when trastuzumab was added to chemotherapy.
In B-31, the no-benefit patient group had high RNA levels of ER,
intermediate levels of HER2, and included mostly luminal A and
B subtypes, although HER2E was also represented (10). As
expected, PIK3CA mutations were not associated with the 8-
gene signature groups, because PIK3CA mutations were not as-
sociated with degree of trastuzumab benefit in the entire B-31
cohort (10). Stromal tumor-infiltrating lymphocytes (sTILs) were
associated with 8-gene signature groups, with the no-benefit
group showing less sTILs, although sTILs alone were not associ-
ated with trastuzumab benefit (11).




PaNo. (%) No. (%)
Age, y
<60 1325 (83.9) 724 (81.2) .09
60 254 (16.1) 168 (18.8)
Tumor size, cm
2 584 (37) 346 (38.8)
2.1–5 842 (53.3) 466 (52.2) .69
>5 152 (9.6) 80 (9.0)
Unknown 1 (0.1)
Nodal status
0 0 118 (13.2) <.001
1–3 896 (56.7) 412 (46.2)
4–9 471 (29.8) 236 (26.5)
10 212 (13.4) 126 (14.1)
ER status
Negative 737 (46.7) 413 (46.3) .09
Positive 842 (53.3) 479 (53.7)
Disease-free survival
Censored 1147 (72.6) 603 (67.6) .09
Event 432 (27.4) 289 (32.4)
aP values were determined using the v2 test and all P values are 2-sided. ER ¼ es-
trogen receptor.
Figure 1. Recurrence-free survival in the 8-gene trastuzumab benefit groups of Alliance/NCCTG N9831. Cox models presented in each legend represent the hazard ratio
for Arm C (adjusted for age, nodes, ER/PR, tumor size, and grade). The last follow-up date was April 25, 2015. Cox models were used to determine P values, which are 2-
sided. CI ¼ confidence interval; ER/PR ¼ estrogen receptor/progesterone receptor.
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The 8-gene signature was statistically significantly associ-
ated with pathological complete response (pCR) in the neoadju-
vant setting in NSABP FB-7 and NRG Oncology/NSABP B-52
using RNA-Seq data (12,13). FB-7 tested the pCR rate in locally-
advanced HER2þ patients treated with chemotherapy-plus-
trastuzumab, or neratinib, or the combination. The pCR rates
were 22% (2/9), 53% (17/32), and 75% (9/12) in the no-, moderate-,
and large-benefit groups, respectively. The pCR rate of the large
group was statistically significantly different from the no-
benefit group (P ¼ .03) (12). B-52 evaluated docetaxel, carbopla-
tin, plus trastuzumab and pertuzumab (TCHP) vs TCHP with es-
trogen deprivation in HER2þ/hormone receptorþ breast cancer.
The 8-gene signature was evaluated in the diagnostic biopsies
of B-52 patients (n¼ 225). A total of 44 (19.6%) patients were
assigned to the no-benefit group, 119 (52.9%) to the moderate-
benefit group, and 62 (27.6%) to the large-benefit group. pCR
rates across both arms were 6.8% in the no-benefit group com-
pared with 54.8% in the large-benefit group (13). The low pCR
rate of the no-benefit group suggests that this cohort may have
derived minimal benefit from HER2-directed therapy. HER2þ/
hormone receptorþ early breast cancer patients have consis-
tently shown a substantially lower pCR rate than patients with
HER2þ/ER- cancers (14). Additionally, differences in long-term
outcomes, based on degree of pathologic response, are less pro-
nounced in the ERþ subset of HER2þ breast cancers (14).
The 8-gene signature may identify an important subset of
HER2þ breast cancers that derive minimal benefit from HER2-
targeted therapy. Additional testing of this signature in other
clinical trials testing dual anti-HER2 therapy such as B-41,
APHINITY, KATHERINE (NCT01772472), and others, will deter-
mine whether any of the predicted trastuzumab benefit groups
received differential benefit from additional anti-HER2 therapy.
All information for testing the 8-gene signature is available in
the Supplementary Material (available online).
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